Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation

Lenalidomide, an immunomodulatory drug (IMiD), is commonly used as a first-line therapy in many haematological cancers, such as multiple myeloma (MM) and 5q myelodysplastic syndromes (5q MDS), and it functions as a molecular glue for the protein degradation of neosubstrates by CRL4(CRBN). Proteolysi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamanaka, Satoshi, Furihata, Hirotake, Yanagihara, Yuta, Taya, Akihito, Nagasaka, Takato, Usui, Mai, Nagaoka, Koya, Shoya, Yuki, Nishino, Kohei, Yoshida, Shuhei, Kosako, Hidetaka, Tanokura, Masaru, Miyakawa, Takuya, Imai, Yuuki, Shibata, Norio, Sawasaki, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439208/
https://www.ncbi.nlm.nih.gov/pubmed/37596276
http://dx.doi.org/10.1038/s41467-023-40385-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439208/
https://www.ncbi.nlm.nih.gov/pubmed/37596276
http://dx.doi.org/10.1038/s41467-023-40385-9

Ejemplares similares